• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬兰患者幽门螺杆菌感染治愈后患胃癌的情况:一项队列研究。

Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study.

机构信息

Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland.

出版信息

Int J Cancer. 2011 Jan 15;128(2):433-9. doi: 10.1002/ijc.25337. Epub 2010 Mar 22.

DOI:10.1002/ijc.25337
PMID:20309944
Abstract

Helicobacter pylori infection is associated with gastric cancer. A total of 97% of the infected subjects have elevated levels of H. pylori antibodies. The antibody titers have been shown to decline rapidly (40-60% within 4-12 months) only after successful eradication therapy. We allocated 26,700 consecutive patients tested during 1986-1998 for H. pylori antibodies to 3 subcohorts: seropositive patients with rapidly falling antibody titers (Hp+CURED, n = 3,650), seropositive patients where no serological information indicating cure was obtained (Hp+NoInfo, n = 11,638) and seronegative patients (Hp-, n = 11,422). In the subcohorts, the standardised incidence ratios (SIRs) with 95% confidence intervals (CI) were defined for subsequent cancers of stomach, pancreas, colon, rectum, breast and prostate separately and for all cancers except stomach combined. The mean follow-up time was 10.1 years and the number of gastric cancers was 72. For the Hp+CURED, the SIR for gastric cancers for the first 5 follow-up years was 1.62 but decreased from the sixth follow-up year thereon to 0.14 (CI: 0.00-0.75). Likewise, the risk ratio, defined in a Poisson regression analysis using the Hp+NoInfo group as the reference, decreased from 1.60 to 0.13 (CI: 0.02-1.00, p = 0.049). The SIR for Hp- was not significantly higher than that for Hp+NoInfo for any of the cancers analysed. To conclude, cured H. pylori infection led to a significantly decreased incidence of gastric cancers from the sixth follow-up year. Advanced atrophic gastritis would be a plausible contributor to the elevated SIR in elderly Hp- patients.

摘要

幽门螺杆菌感染与胃癌有关。感染的受试者中有 97%的人幽门螺杆菌抗体水平升高。已经表明,只有在成功根除治疗后,抗体滴度才会迅速下降(4-12 个月内下降 40-60%)。我们将 1986 年至 1998 年间检测到的 26700 例连续患者的幽门螺杆菌抗体分为 3 个亚组:抗体滴度迅速下降的血清阳性患者(Hp+CURED,n=3650)、未获得任何血清学信息表明治愈的血清阳性患者(Hp+NoInfo,n=11638)和血清阴性患者(Hp-,n=11422)。在这些亚组中,定义了随后胃癌、胰腺癌、结肠癌、直肠癌、乳腺癌和前列腺癌以及除胃癌以外的所有癌症的标准化发病比(SIR)及其 95%置信区间(CI)。平均随访时间为 10.1 年,胃癌病例数为 72 例。对于 Hp+CURED,前 5 年的胃癌 SIR 为 1.62,但从第 6 年开始,该比值下降至 0.14(CI:0.00-0.75)。同样,使用 Hp+NoInfo 组作为参考,在泊松回归分析中定义的风险比从 1.60 下降至 0.13(CI:0.02-1.00,p=0.049)。对于任何分析的癌症,Hp-的 SIR 均未显著高于 Hp+NoInfo。总之,治愈的幽门螺杆菌感染导致从第 6 年开始胃癌的发病率显著下降。晚期萎缩性胃炎可能是老年 Hp-患者 SIR 升高的一个合理因素。

相似文献

1
Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study.芬兰患者幽门螺杆菌感染治愈后患胃癌的情况:一项队列研究。
Int J Cancer. 2011 Jan 15;128(2):433-9. doi: 10.1002/ijc.25337. Epub 2010 Mar 22.
2
Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period.幽门螺杆菌IgA和IgG抗体、血清胃蛋白酶原I与胃癌风险:延长随访期后风险的变化
Int J Cancer. 2006 Aug 1;119(3):702-5. doi: 10.1002/ijc.21884.
3
[Changes of gastric mucosa histopathology after Helicobacter pylori eradication].[幽门螺杆菌根除后胃黏膜组织病理学变化]
Zhonghua Nei Ke Za Zhi. 2003 Mar;42(3):162-4.
4
Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study.幽门螺杆菌根除与胃癌及胃黏膜组织学变化的关系:一项10年随访研究
Chin Med J (Engl). 2014;127(8):1454-8.
5
[The effects of eradication therapy in patients with chronic atrophic gastritis and seropositivity for anti-HP antibodies and histological negativity for Helicobacter pylori].[根除治疗对慢性萎缩性胃炎且抗幽门螺杆菌抗体血清学阳性但幽门螺杆菌组织学阴性患者的影响]
Clin Ter. 1999 Sep-Oct;150(5):343-6.
6
Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.基于血清胃蛋白酶原和幽门螺杆菌抗体滴度评估的慢性活动性胃炎和由此导致的胃萎缩与癌症发展的关系。
Int J Cancer. 2014 Mar 15;134(6):1445-57. doi: 10.1002/ijc.28470. Epub 2013 Oct 3.
7
Risk of gastric cancer in Helicobacter pylori infection in a 15-year follow-up.幽门螺杆菌感染15年随访中胃癌的风险
Scand J Gastroenterol. 2016 Oct;51(10):1159-64. doi: 10.1080/00365521.2016.1183225. Epub 2016 Jun 24.
8
Different etiological role of Helicobacter pylori (Hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers: a nested case-control study using IgG titer against Hp surface antigen.幽门螺杆菌(Hp)感染在分化型和未分化型胃癌致癌过程中的不同病因学作用:一项针对Hp表面抗原IgG滴度的巢式病例对照研究
Acta Oncol. 2008;47(3):360-5. doi: 10.1080/02841860701843035.
9
Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study.根除幽门螺杆菌感染可改善胃黏膜萎缩,预防肠上皮化生进展,尤其在老年人群中:一项长期前瞻性队列研究。
J Gastroenterol Hepatol. 2010 Mar;25(3):544-7. doi: 10.1111/j.1440-1746.2009.05995.x. Epub 2009 Oct 6.
10
Clinical significance of IgG antibody titer against Helicobacter pylori.抗幽门螺杆菌IgG抗体滴度的临床意义
Helicobacter. 2009 Jun;14(3):231-6. doi: 10.1111/j.1523-5378.2009.00681.x.

引用本文的文献

1
Prevention of Gastric Cancer: Treatment.胃癌的预防:治疗。
Korean J Helicobacter Up Gastrointest Res. 2024 Sep;24(3):238-242. doi: 10.7704/kjhugr.2024.0031. Epub 2024 Sep 9.
2
Endoscopic risk factors to inform early detection of gastric cancer after eradication: Meta-analysis and systematic review.用于指导根除治疗后胃癌早期检测的内镜危险因素:荟萃分析与系统评价
DEN Open. 2025 Feb 26;5(1):e70086. doi: 10.1002/deo2.70086. eCollection 2025 Apr.
3
Exploring the Link Between Obligate Anaerobe-Related Dysbiosis and Prostate Cancer Development: A Pilot Study.
探索专性厌氧菌相关的生态失调与前列腺癌发生之间的联系:一项初步研究。
Cancers (Basel). 2024 Dec 29;17(1):70. doi: 10.3390/cancers17010070.
4
Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of infection: a systematic review and meta-analysis.益生菌补充铋四联疗法治疗 感染的疗效和安全性:系统评价和荟萃分析。
J Int Med Res. 2023 Oct;51(10):3000605231203841. doi: 10.1177/03000605231203841.
5
Antibiotic resistance characteristics and risk factors analysis of strains isolated from patients in Liaoning Province, an area in North China.华北地区辽宁省患者分离菌株的抗生素耐药特征及危险因素分析。
PeerJ. 2023 May 16;11:e15268. doi: 10.7717/peerj.15268. eCollection 2023.
6
In Vitro Activity of the Arylaminoartemisinin GC012 against and Its Effects on Biofilm.芳基氨基青蒿素GC012的体外活性及其对生物膜的影响。
Pathogens. 2022 Jun 29;11(7):740. doi: 10.3390/pathogens11070740.
7
Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer.早期胃癌的病因学、内镜检测及管理进展
Cancers (Basel). 2021 Dec 13;13(24):6242. doi: 10.3390/cancers13246242.
8
eradication: Exploring its impacts on the gastric mucosa.根除:探索其对胃黏膜的影响。
World J Gastroenterol. 2021 Aug 21;27(31):5152-5170. doi: 10.3748/wjg.v27.i31.5152.
9
Effect of Temperature on Metronidazole Resistance in .温度对……中甲硝唑耐药性的影响
Front Microbiol. 2021 May 19;12:681911. doi: 10.3389/fmicb.2021.681911. eCollection 2021.
10
Chemoprevention Against Gastric Cancer.胃癌的化学预防
Gastrointest Endosc Clin N Am. 2021 Jul;31(3):519-542. doi: 10.1016/j.giec.2021.03.006.